| Ytd | 59.23% | |
| 1y | 97.77% |
| Open | 183.15 | Prev Close | 185.04 | Low | 178.52 | High | 183.33 | Mkt Cap | 10.60B |
| Vol | 587.93K | Avg Vol | 800.54K | EPS | -3.27 | P/E | N/A | Forward P/E | 356.79 |
| Beta | 0.76 | Short Ratio | 4.59 | Inst. Own | 105.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-28 | 50-d Avg | 168.23 | 200-d Avg | 130.22 | 1yr Est | 197.15 |
GKOS News
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized bas
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
UBS analyst Patrick Wood maintains Glaukos (NYSE:GKOS) with a Neutral and raises the price target
HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the p
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta
Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and raises the
Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f
Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th
Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th
Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
Glaukos (NYSE:GKOS) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 m
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.14) per share which beat the analyst consensus
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f
Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta
HC Wainwright & Co. analyst Yi Chen initiates coverage on Glaukos (NYSE:GKOS) with a Buy rati
Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and maintains
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J
Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta
Wall Street analysts change outlook on top stocks. For full list of changes including upgrades/downg
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
JP Morgan analyst Allen Gong maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta
US stocks mixed, Dow up 400 pts. Caterpillar, Bandwidth, Everspin, Vistance, IMPINJ, Novocure, Viavi
Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th
Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
New J-code for Epioxa™, J2789, set to become effective July 1, 2026Glaukos Corporation (NYSE:GKOS),
Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th
Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target
Glaukos (NYSE:GKOS) affirms FY2026 sales outlook from $600.000 million-$620.000 million to $600.000
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.28) per share which missed the analyst consensu
